Li, Dan
Johmura, Yoshikazu https://orcid.org/0000-0002-6812-9607
Morimoto, Satoru
Doi, Miyuki
Nakanishi, Keiko
Ozawa, Manabu
Tsunekawa, Yuji
Inoue-Yamauchi, Akane
Naruse, Hiroya https://orcid.org/0000-0002-1190-0499
Matsukawa, Takashi
Takeshita, Yukio https://orcid.org/0000-0002-0314-550X
Suzuki, Naoki https://orcid.org/0000-0001-8880-8554
Aoki, Masashi
Nishiyama, Ayumi
Zeng, Xin
Konishi, Chieko
Suzuki, Narumi https://orcid.org/0000-0001-6024-9949
Nishiyama, Atsuya https://orcid.org/0000-0002-8416-3776
Harris, Alexander Stephen https://orcid.org/0009-0003-1005-3691
Morita, Mariko
Yamaguchi, Kiyoshi https://orcid.org/0000-0003-2113-4369
Furukawa, Yoichi
Nakai, Kenta https://orcid.org/0000-0002-8721-8883
Tsuji, Shoji https://orcid.org/0000-0001-5602-5686
Yamazaki, Satoshi https://orcid.org/0000-0003-4249-3854
Yamanashi, Yuji
Shimada, Shoichi
Okada, Takashi
Okano, Hideyuki https://orcid.org/0000-0001-7482-5935
Toda, Tatsushi https://orcid.org/0000-0002-0717-1123
Nakanishi, Makoto https://orcid.org/0000-0002-6707-3584
Funding for this research was provided by:
Japan Agency for Medical Research and Development (21zf0127003, 21cm0106175, 21gm5010001, 214600040, 21bm0804027, 22bm0804003, 21wm0425009, 21ek0109492)
MEXT | Japan Society for the Promotion of Science (20H00514, 19H05740, JP18H05026m, JP16H06148, JP16K15238, JP22K15736, JP21H05273, JP20H00485)
Princess Takamatsu Cancer Research Fund
Article History
Received: 8 October 2021
Accepted: 29 June 2023
First Online: 20 July 2023
Competing interests
: M.N. is a scientific advisor to Airweave and reverSASP Therapeutics and a shareholder of reverSASP Therapeutics. All other authors declare no competing interests.